BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with Merck’s Keytruda (pembrolizumab) for Solid Tumors

Shots:

• In July’2019, Bioinvent reports the FDA’s acceptance of its IND application of BI-1206 + Keytruda combination therapy based on the preclinical data demonstrating that BI-1206 enhances anti-tumor immune responses in patients with solid tumors
• BioInvent will evaluate the combination therapy in P-I/IIa study in patients with an advanced solid tumor, prior treated with anti-PD1 or anti-PD-L1 antibodies
• BioInvent’s BI-1206 is an anti- FcγRllB antibodies, currently being investigated in non-Hodgkin lymphoma and chronic lymphocytic leukemia and has received FDA’s OD designation for mantle cell lymphoma in 2019

Click here to­ read full press release/ article | Ref: BioInvent | Image: Nordic Life Science Insight